Maven Capital Partners is the famous VC, which was founded in 2009. The fund was located in Europe if to be more exact in United Kingdom. The leading representative office of defined VC is situated in the Glasgow.
The usual cause for the fund is to invest in rounds with 1-2 partakers. Despite the Maven Capital Partners, startups are often financed by Scottish Investment Bank, Par Equity, Development Bank of Wales. The meaningful sponsors for the fund in investment in the same round are Development Bank of Wales, Seneca Partners, NVM Private Equity. In the next rounds fund is usually obtained by Seneca Partners, Development Bank of Wales, Downing Ventures.
Among the most popular portfolio startups of the fund, we may highlight Global Risk Partners, Hiring Hub, ITS Technology Group. Among the most popular fund investment industries, there are Automotive, Biotechnology. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.
The average startup value when the investment from Maven Capital Partners is 5-10 millions dollars. The fund is constantly included in 7-12 deals per year. The high activity for fund was in 2019. The real fund results show that this VC is 52 percentage points more often commits exit comparing to other companies. Opposing the other organizations, this Maven Capital Partners works on 21 percentage points less the average amount of lead investments. The common things for fund are deals in the range of 1 - 5 millions dollars. The higher amount of exits for fund were in 2017.
Besides them, we counted 27 critical employees of this fund in our database.
Related Funds
Funds with similar focus
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Carcinotech | $5M | 29 Jan 2024 | - | ||
Metrion Biosciences | $5M | 20 Dec 2023 | Cambridge, England, United Kingdom | ||
Laverock Therapeutics | $18M | 28 Sep 2023 | - | ||
MarraBio | $685K | 18 Sep 2023 | Newcastle upon Tyne, North East, United Kingdom | ||
Manufacture 2030 | $6M | 28 Mar 2023 | Oxford, England, United Kingdom | ||
Biorelate | $8M | 29 Nov 2022 | Oldham, England, United Kingdom | ||
Summize | $6M | 25 Oct 2022 | Manchester, Greater Manchester, United Kingdom | ||
Bright | $4M | 20 Oct 2022 | London, England, United Kingdom | ||
Novatus Advisory | $5M | 11 Jul 2022 | Hampshire, England, United Kingdom |
– Class Technologies, an edtech platform, has raised a $105M Series B round.
– Led by the Softbank Vision Fund, the round also includes GSV Ventures, Emergence Capital, Maven Partners, Owl Ventures, Insight Partners, SWaN & Legend Venture Partners, Rise of the Rest Fund, Learn Capital, Reach Capital, Slow Ventures, Sound Ventures, Chimera Investment, Daher Capital, Guy Oseary, Bill Tai and Tom Brady.
– The company was founded by education software pioneer Michael Chasen.
– Class Technologies Inc. from Washington, DC develops a platform enhancing virtual and hybrid classrooms by adding teaching and learning tools to Zoom.
– Series B $105m round was led by SoftBank’s Vision Fund 2 and participated by GSV Ventures, Emergence Capital, Maven Partners, Owl Ventures, Insight Partners, SWaN & Legend Venture Partners, Revolution’s Rise of the Rest Fund, Learn Capital, Reach Capital, Slow Ventures, Sound Ventures, Chimera Investment, Daher Capital, Guy Oseary, Bill Tai, and Super Bowl champion and entrepreneur Tom Brady.
– The new investment will be used to accelerate growth and expand globally into new markets.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Carcinotech | $5M | 29 Jan 2024 | - | ||
Metrion Biosciences | $5M | 20 Dec 2023 | Cambridge, England, United Kingdom | ||
Laverock Therapeutics | $18M | 28 Sep 2023 | - | ||
MarraBio | $685K | 18 Sep 2023 | Newcastle upon Tyne, North East, United Kingdom | ||
Manufacture 2030 | $6M | 28 Mar 2023 | Oxford, England, United Kingdom | ||
Biorelate | $8M | 29 Nov 2022 | Oldham, England, United Kingdom | ||
Summize | $6M | 25 Oct 2022 | Manchester, Greater Manchester, United Kingdom | ||
Bright | $4M | 20 Oct 2022 | London, England, United Kingdom | ||
Novatus Advisory | $5M | 11 Jul 2022 | Hampshire, England, United Kingdom |
